213 related articles for article (PubMed ID: 27649523)
1. Late-onset pompe disease in Iran: A clinical and genetic report.
Nazari F; Sinaei F; Nilipour Y; Fatehi F; Streubel B; Ashrafi MR; Aryani O; Nafissi S
Muscle Nerve; 2017 Jun; 55(6):835-840. PubMed ID: 27649523
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
[TBL] [Abstract][Full Text] [Related]
3. Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
Kroos MA; Pomponio RJ; Hagemans ML; Keulemans JL; Phipps M; DeRiso M; Palmer RE; Ausems MG; Van der Beek NA; Van Diggelen OP; Halley DJ; Van der Ploeg AT; Reuser AJ
Neurology; 2007 Jan; 68(2):110-5. PubMed ID: 17210890
[TBL] [Abstract][Full Text] [Related]
4. Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations.
Oba-Shinjo SM; da Silva R; Andrade FG; Palmer RE; Pomponio RJ; Ciociola KM; S Carvalho M; Gutierrez PS; Porta G; Marrone CD; Munoz V; Grzesiuk AK; Llerena JC; Berditchevsky CR; Sobreira C; Horovitz D; Hatem TP; Frota ER; Pecchini R; Kouyoumdjian JA; Werneck L; Amado VM; Camelo JS; Mattaliano RJ; Marie SK
J Neurol; 2009 Nov; 256(11):1881-90. PubMed ID: 19588081
[TBL] [Abstract][Full Text] [Related]
5. A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.
Herzog A; Hartung R; Reuser AJ; Hermanns P; Runz H; Karabul N; Gökce S; Pohlenz J; Kampmann C; Lampe C; Beck M; Mengel E
Orphanet J Rare Dis; 2012 Jun; 7():35. PubMed ID: 22676651
[TBL] [Abstract][Full Text] [Related]
6. Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study.
Semplicini C; Letard P; De Antonio M; Taouagh N; Perniconi B; Bouhour F; Echaniz-Laguna A; Orlikowski D; Sacconi S; Salort-Campana E; Solé G; Zagnoli F; Hamroun D; Froissart R; Caillaud C; Laforêt P;
J Inherit Metab Dis; 2018 Nov; 41(6):937-946. PubMed ID: 30155607
[TBL] [Abstract][Full Text] [Related]
7. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.
Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS
Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071
[TBL] [Abstract][Full Text] [Related]
8. A Comprehensive Update on Late-Onset Pompe Disease.
Labella B; Cotti Piccinelli S; Risi B; Caria F; Damioli S; Bertella E; Poli L; Padovani A; Filosto M
Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759679
[TBL] [Abstract][Full Text] [Related]
9. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population.
Musumeci O; la Marca G; Spada M; Mondello S; Danesino C; Comi GP; Pegoraro E; Antonini G; Marrosu G; Liguori R; Morandi L; Moggio M; Massa R; Ravaglia S; Di Muzio A; Filosto M; Tonin P; Di Iorio G; Servidei S; Siciliano G; Angelini C; Mongini T; Toscano A;
J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):5-11. PubMed ID: 25783438
[TBL] [Abstract][Full Text] [Related]
10. The frequency of late-onset Pompe disease in pediatric patients with limb-girdle muscle weakness and nonspecific hyperCKemia: A multicenter study.
Ünver O; Hacıfazlıoğlu NE; Karatoprak E; Güneş AS; Sağer G; Kutlubay B; Sözen G; Saltık S; Yılmaz K; Kara B; Türkdoğan D
Neuromuscul Disord; 2016 Nov; 26(11):796-800. PubMed ID: 27666774
[TBL] [Abstract][Full Text] [Related]
11. First clinical and genetic description of a family diagnosed with late-onset Pompe disease from Costa Rica.
Torrealba-Acosta G; Rodríguez-Roblero MC; Bogantes-Ledezma S; Carazo-Céspedes K; Desnuelle C
Neuromuscul Disord; 2017 Oct; 27(10):951-955. PubMed ID: 28694071
[TBL] [Abstract][Full Text] [Related]
12. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy.
Pascarella A; Terracciano C; Farina O; Lombardi L; Esposito T; Napolitano F; Franzese G; Panella G; Tuccillo F; la Marca G; Bernardini S; Boffo S; Giordano A; Di Iorio G; Melone MAB; Sampaolo S
J Cell Physiol; 2018 Aug; 233(8):5829-5837. PubMed ID: 29215735
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid α-glucosidase activity.
Bali DS; Tolun AA; Goldstein JL; Dai J; Kishnani PS
Muscle Nerve; 2011 May; 43(5):665-70. PubMed ID: 21484825
[TBL] [Abstract][Full Text] [Related]
14. A newly identified c.1824_1828dupATACG mutation in exon 13 of the GAA gene in infantile-onset glycogen storage disease type II (Pompe disease).
Aryani O; Manshadi MD; Tondar M; Khalili E; Kamalidehghan B; Ahmadipour F; Fani S; Houshmand M
Mol Biol Rep; 2014 Sep; 41(9):6211-4. PubMed ID: 24976573
[TBL] [Abstract][Full Text] [Related]
15. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies.
Preisler N; Lukacs Z; Vinge L; Madsen KL; Husu E; Hansen RS; Duno M; Andersen H; Laub M; Vissing J
Mol Genet Metab; 2013 Nov; 110(3):287-9. PubMed ID: 24011652
[TBL] [Abstract][Full Text] [Related]
16. Novel GAA mutations in patients with Pompe disease.
Turaça LT; de Faria DO; Kyosen SO; Teixeira VD; Motta FL; Pessoa JG; Rodrigues E Silva M; de Almeida SS; D'Almeida V; Munoz Rojas MV; Martins AM; Pesquero JB
Gene; 2015 Apr; 561(1):124-31. PubMed ID: 25681614
[TBL] [Abstract][Full Text] [Related]
17. Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families.
Napolitano F; Bruno G; Terracciano C; Franzese G; Palomba NP; Scotto di Carlo F; Signoriello E; De Blasiis P; Navarro S; Gialluisi A; Melone MAB; Sampaolo S; Esposito T
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807278
[TBL] [Abstract][Full Text] [Related]
18. Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.
Wens SC; Kroos MA; de Vries JM; Hoogeveen-Westerveld M; Wijgerde MG; van Doorn PA; van der Ploeg AT; Reuser AJ
Mol Genet Metab; 2012 Nov; 107(3):485-9. PubMed ID: 23000108
[TBL] [Abstract][Full Text] [Related]
19. Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum.
Musumeci O; Thieme A; Claeys KG; Wenninger S; Kley RA; Kuhn M; Lukacs Z; Deschauer M; Gaeta M; Toscano A; Gläser D; Schoser B
Neuromuscul Disord; 2015 Sep; 25(9):719-24. PubMed ID: 26231297
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic implications of pathogenic variant types in Pompe disease.
Viamonte MA; Filipp SL; Zaidi Z; Gurka MJ; Byrne BJ; Kang PB
J Hum Genet; 2021 Nov; 66(11):1089-1099. PubMed ID: 33972680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
